FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2905974789> ?p ?o ?g. }

• W2905974789 endingPage "S70" @default.
• W2905974789 startingPage "S70" @default.
• W2905974789 abstract "Frontline treatment (FL) with VTD is considered standard of care in MM patients who are transplant eligible 1. This analysis was conducted to understand the real-world usage of VTD as FL treatment in SCT eligible setting across EU5 countries. Real world data were collected through Adelphi’s Disease-Specific ProgrammeTM - a point in time survey administered to physicians (n=241) in EU5 countries between Nov 2017 – Feb 2018. SCT eligibility and treatments, including number of cycles and dosage, were collected from patient record forms (n=1952). Response and outcomes from completed lines of therapy were captured. Summary statistics were reported and analysed descriptively. 29% (n=572) of patients received SCT in FL or were classified as SCT eligible. Half of these patients (n=298) are currently treated (“Current Patients”, n=166) or have received VTD as FL induction regimen in the past (“Past Patients”; n=132). In Past Patients, half of them were intended to be administered 4 VTD cycles and 40% 6 cycles. In Current Patients, there is an inversion on the intended treatment length with physicians planning to use 6 cycles in more than half of the patients (54%). 39% (n=52) of patients that received or plan to receive 6 cycles use(d) the following dosing schedule: 4-week cycle with bortezomib 1.3mg/m2 administered twice weekly on weeks 1-2 and thalidomide 100 mg daily; the dose and frequency of dexamethasone administration varied largely among patients. Response outcomes for patients that completed 4 (n=70) and 6 cycles (n=43) were: 39% and 47% received an MRD test of which 67% and 50% were negative; 70% and 60% achieved ≥CR and 24% and 26% VGPR, respectively. We identified a trend to increase the number of VTD cycles as induction regimen in transplant eligible patients. References: [1] Moreau P et al. Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv6." @default.
• W2905974789 created "2019-01-01" @default.
• W2905974789 creator A5017972624 @default.
• W2905974789 creator A5027638497 @default.
• W2905974789 creator A5065009288 @default.
• W2905974789 creator A5075665527 @default.
• W2905974789 date "2018-10-01" @default.
• W2905974789 modified "2023-09-26" @default.
• W2905974789 title "PCN332 - REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES" @default.
• W2905974789 doi "https://doi.org/10.1016/j.jval.2018.09.414" @default.
• W2905974789 hasPublicationYear "2018" @default.
• W2905974789 type Work @default.
• W2905974789 sameAs 2905974789 @default.
• W2905974789 citedByCount "0" @default.
• W2905974789 crossrefType "journal-article" @default.
• W2905974789 hasAuthorship W2905974789A5017972624 @default.
• W2905974789 hasAuthorship W2905974789A5027638497 @default.
• W2905974789 hasAuthorship W2905974789A5065009288 @default.
• W2905974789 hasAuthorship W2905974789A5075665527 @default.
• W2905974789 hasBestOaLocation W29059747891 @default.
• W2905974789 hasConcept C126322002 @default.
• W2905974789 hasConcept C187212893 @default.
• W2905974789 hasConcept C2776364478 @default.
• W2905974789 hasConcept C2777288759 @default.
• W2905974789 hasConcept C2777478702 @default.
• W2905974789 hasConcept C2779609412 @default.
• W2905974789 hasConcept C2780401358 @default.
• W2905974789 hasConcept C2781413609 @default.
• W2905974789 hasConcept C71924100 @default.
• W2905974789 hasConceptScore W2905974789C126322002 @default.
• W2905974789 hasConceptScore W2905974789C187212893 @default.
• W2905974789 hasConceptScore W2905974789C2776364478 @default.
• W2905974789 hasConceptScore W2905974789C2777288759 @default.
• W2905974789 hasConceptScore W2905974789C2777478702 @default.
• W2905974789 hasConceptScore W2905974789C2779609412 @default.
• W2905974789 hasConceptScore W2905974789C2780401358 @default.
• W2905974789 hasConceptScore W2905974789C2781413609 @default.
• W2905974789 hasConceptScore W2905974789C71924100 @default.
• W2905974789 hasLocation W29059747891 @default.
• W2905974789 hasOpenAccess W2905974789 @default.
• W2905974789 hasPrimaryLocation W29059747891 @default.
• W2905974789 hasRelatedWork W1963690178 @default.
• W2905974789 hasRelatedWork W1999964913 @default.
• W2905974789 hasRelatedWork W2003559211 @default.
• W2905974789 hasRelatedWork W2013163224 @default.
• W2905974789 hasRelatedWork W2088313945 @default.
• W2905974789 hasRelatedWork W2112489854 @default.
• W2905974789 hasRelatedWork W2427804748 @default.
• W2905974789 hasRelatedWork W2621719068 @default.
• W2905974789 hasRelatedWork W2980910443 @default.
• W2905974789 hasRelatedWork W3127479238 @default.
• W2905974789 hasVolume "21" @default.
• W2905974789 isParatext "false" @default.
• W2905974789 isRetracted "false" @default.
• W2905974789 magId "2905974789" @default.
• W2905974789 workType "article" @default.